Peptide Therapy San Antonio & Boerne
Physician-supervised peptide protocols — Sermorelin, CJC-1295/Ipamorelin, NAD+, and more — individualized to your labs and goals by Dr. Jamie Lynn Jaqua, MD.
Medically reviewed by Dr. Jamie Lynn Jaqua, MD
What Is HGH Peptide Therapy?
Human growth hormone (HGH) declines naturally as we age — and the effects compound over time. Peptide therapy uses compounds like Sermorelin (a synthetic analog of Growth Hormone Releasing Hormone) to stimulate the body's own pituitary gland to produce and release growth hormone naturally.
This is fundamentally different from injecting synthetic HGH directly, which carries greater risks and side effects. Peptide therapy works with your body's own physiology — making it a lower-risk, clinically supported approach to restoring growth hormone function.
A study published in Clinical Endocrinology found Sermorelin effective at increasing GH levels, improving muscle mass, bone density, and body composition.
Signs Your Growth Hormone May Be Low
Body & Metabolism
- Weight gain and difficulty losing weight despite effort
- Slower metabolism
- Loss of muscle mass and strength
Energy & Sleep
- Persistent fatigue and low energy
- Poor sleep quality
Brain & Mood
- Brain fog and difficulty concentrating
- Anxiety, depression, or low mood
Other Signs
- Low libido and reduced sexual performance
- Dry, aging, or thinning skin
POTENTIAL Benefits of HGH Peptide Therapy
Body Composition & Performance
- Reduces body fat and supports weight loss
- Improves muscle mass and physical strength
- Enhances endurance and athletic performance
- Optimizes metabolism
Sexual Health
- Enhances sex drive and sexual performance
- Supports symptoms of menopause and andropause
Energy & Recovery
- Increases energy and motivation
- Improves sleep quality and duration
- Supports immune function
Brain & Mood
- Improves mental clarity, alertness, and memory
- Helps with anxiety and depression
- Elevates mood
Skin & Longevity
- Anti-aging and regenerative properties
- Improves skin elasticity, reduces wrinkles
- Supports cholesterol and blood pressure
HGH peptide therapy delivers the documented benefits of growth hormone optimization — at a fraction of the cost and risk of synthetic HGH.
Learn more about specific peptides: Sermorelin, CJC-1295/Ipamorelin, NAD+, Semaglutide
Am I a Candidate for Peptide Therapy?Pricing is reviewed during your free consultation — no hidden costs.
Our Peptide Portfolio
At Vitality Texas, Dr. Jaqua offers a range of physician-supervised peptide protocols tailored to each patient's goals and lab results. Every protocol begins with a comprehensive evaluation — no peptide is prescribed without reviewing your labs, health history, and clinical picture.
Current protocols available at Vitality Texas include:
- Sermorelin — A GHRH analog that stimulates the pituitary gland to produce and release growth hormone naturally. The most established growth hormone peptide in physician-supervised use.
- CJC-1295 + Ipamorelin — A GH secretagogue stack combining a long-acting GHRH analog with a selective GH secretagogue. Used by physicians for robust, pulsatile growth hormone stimulation in patients whose IGF-1 and GH axis markers indicate deficiency.
- NAD+ — A cellular coenzyme supporting mitochondrial energy production and DNA repair. Available via injectable subcutaneous delivery at Vitality Texas. NAD+ was never on the restricted compound list and remains available via licensed compounding pharmacy with a physician prescription.
- TB-500 — Studied in animal models for tissue recovery and repair support. Used by physicians in the context of supervised protocols for patients with recovery needs. TB-500 is among the peptides expected to be reclassified under the February 2026 HHS announcement — physician-supervised access is available pending formal FDA publication.
The peptide regulatory landscape changed significantly in February 2026. See our guide to peptide therapy FDA status 2026 for the latest updates on which peptides are expected to return to legal compounding access.
Growth Hormone Peptides: Sermorelin and CJC-1295/Ipamorelin
Growth hormone (GH) is produced by the pituitary gland and peaks in early adulthood. After the age of 30, GH levels typically decline at approximately 15% per decade — a process called somatopause. Lower GH levels correlate with changes in body composition (increased fat, decreased muscle), reduced sleep quality, lower energy, and slower recovery from physical activity.
Growth hormone peptides work through the pituitary-GH axis — they stimulate the pituitary to produce and release GH in natural pulsatile patterns rather than introducing synthetic GH directly. This approach preserves the body's own regulatory feedback loops and is associated with a more favorable safety profile compared to direct HGH injection.
Sermorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). It binds to GHRH receptors in the pituitary and stimulates natural GH release. Sermorelin has been used in physician-supervised settings for decades and has a well-documented tolerability profile.
CJC-1295 + Ipamorelin is a combination protocol that pairs a long-acting GHRH analog (CJC-1295) with a selective GH secretagogue (Ipamorelin). The combination produces robust, sustained GH stimulation. CJC-1295 extends the half-life of the GHRH signal; Ipamorelin amplifies GH release without significantly affecting cortisol or prolactin — two hormones that can be problematic with other secretagogues.
Adults 35 and older who are experiencing fatigue, changes in body composition, disrupted sleep, or reduced recovery capacity may be candidates for GH peptide therapy. Dr. Jaqua evaluates IGF-1 and growth hormone levels at baseline to determine the optimal protocol — and whether Sermorelin or the CJC-1295/Ipamorelin stack is the more appropriate starting point.
Learn more: Sermorelin | CJC-1295 + Ipamorelin
Recovery Peptides: TB-500
TB-500 (Thymosin Beta-4) is a naturally occurring peptide found in virtually all human and animal tissues. It has been studied in animal models for its role in tissue recovery and repair support — including muscle, tendon, ligament, and cardiac tissue. Patients who work with physicians for recovery support may be evaluated for TB-500 protocols based on individual clinical circumstances.
It is important to note that human randomized controlled trial (RCT) data for TB-500 in clinical populations is limited. The research base is predominantly animal model studies. Dr. Jaqua will review the current evidence with you and discuss whether your situation warrants a physician-supervised protocol.
TB-500 is among the peptides expected to be reclassified under the February 2026 HHS announcement — pending formal FDA publication. Current physician-supervised access continues under existing compounding protocols. Dr. Jaqua will update protocols when formal guidance is published.
Regarding BPC-157: BPC-157 is also under regulatory review. We will update this section when the regulatory status is formally published. BPC-157 is not currently available as part of Vitality Texas peptide protocols pending this review.
Learn more: TB-500 | Peptide Therapy FDA Status 2026
Cellular Energy and Longevity: NAD+
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell of the body. It plays a central role in mitochondrial energy production (the ATP cycle) and is required for DNA repair, cellular signaling, and the activation of sirtuins — proteins associated with longevity and metabolic regulation. NAD+ levels decline with age, and declining NAD+ is associated with reduced cellular energy efficiency and increased metabolic dysfunction.
At Vitality Texas, NAD+ is administered via subcutaneous injection — a delivery method distinct from IV infusion. Subcutaneous delivery allows for convenient at-home administration following an in-clinic initiation. For patients who prefer intravenous delivery or who are receiving NAD+ as part of a broader nutrient therapy protocol, see our IV therapy program.
Importantly, NAD+ was never placed on the FDA's restricted compound list (Category 2). It remains available via licensed compounding pharmacy with a physician prescription — without the regulatory uncertainty that currently affects some other peptides.
Patients who may benefit from NAD+ therapy include those experiencing persistent fatigue, metabolic slowdown, cognitive fog, or those seeking cellular support alongside a TRT or GLP-1 weight loss program. Dr. Jaqua will evaluate whether NAD+ is appropriate as a standalone protocol or as a complement to your existing care.
Learn more: NAD+ Therapy at Vitality Texas
The 2026 Peptide Regulatory Update
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 peptides previously classified as Category 2 — and thus restricted from legal compounding — are expected to be reclassified to Category 1, restoring legal physician-supervised compounding access. This announcement was initially made on the Joe Rogan Experience podcast (#2461) and later covered by NPR and multiple health publications.
The 14 peptides expected to return include BPC-157, TB-500, Thymosin Alpha-1, AOD-9604, Ipamorelin, CJC-1295, and others. As of April 2026, the formal FDA publication of the updated list has not yet been released. Compounding pharmacies cannot legally resume production of previously restricted peptides until the official FDA document is published.
What this means for Vitality Texas patients:
- Current physician-supervised protocols (Sermorelin, CJC-1295/Ipamorelin, NAD+, TB-500) are unaffected by this transition.
- When the formal FDA publication is released, Vitality Texas will evaluate expanding its protocol offerings to include previously restricted peptides — beginning with BPC-157, subject to Bailey/legal clearance.
- Patients will be notified through clinic communications when new protocols become available.
For a full explanation of the announcement, what was restricted, what is expected to return, and what it means for patients, see our in-depth article: Peptide Therapy FDA Status 2026: What the RFK/HHS Announcement Means for Patients.
Peptide Therapy Questions & Answers
Common questions about physician-supervised peptide therapy at Vitality Texas.
Peptide Therapy — In-Depth Resources
Physician-reviewed articles on peptide therapy, regulatory updates, and individual peptide protocols.
Serving patients in:
References
- Walker RF. “Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency?” Clin Interv Aging. 2006;1(4):307–308. PMID: 18046908
- Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sex Med Rev. 2018;6(1):45–53. DOI: 10.1016/j.sxmr.2017.02.004
- Svensson J, Lönn L, Jansson JO, et al. “Two-Month Treatment with MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure.” J Clin Endocrinol Metab. 1998;83(2):362–369. DOI: 10.1210/jcem.83.2.4553
- Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.” Cell Metabolism. 2018;27(3):529–547. DOI: 10.1016/j.cmet.2018.02.011
Restore Your Growth Hormone Levels Naturally
Peptide therapy works with your body's own physiology — a lower-risk, clinically supported path to better energy, sleep, and body composition. Talk to Dr. Jaqua, serving patients in San Antonio and Boerne, TX.
Free consultation · No commitment · Results-focused care
Already a patient? Download your intake form